Showing results (1-10 of 736) with videos related to
Sort By:
Pageof 74
Cell Cycle (Georgetown, Tex.)|June 23, 2005
JAK2 in myeloproliferative disorders is not just another kinaseAyalew Tefferi, D Gary GillilandMayo Clinic Proceedings|July 13, 2005
The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosisAyalew Tefferi, D Gary GillilandCell Cycle (Georgetown, Tex.)|March 14, 2007
Oncogenes in myeloproliferative disordersAyalew Tefferi, D Gary GillilandNature Reviews. Cancer|August 28, 2007
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disordersRoss L Levine, Animesh Pardanani, Ayalew Tefferi, et al.Blood|November 17, 2007
Host genetic variation contributes to phenotypic diversity in myeloproliferative disordersAnimesh Pardanani, Brooke L Fridley, Terra L Lasho, et al.British Journal of Haematology|November 17, 2006
Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over timeTerra L Lasho, Animesh Pardanani, Rebecca F McClure, et al.American Journal of Hematology|November 17, 2011
Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and managementAyalew TefferiCurrent Opinion in Hematology|February 4, 2006
New insights into the pathogenesis and drug treatment of myelofibrosisAyalew TefferiSeminars in Hematology|April 12, 2003
Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the newAyalew TefferiPageof 74